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Abstract
The interaction between the tumor cells in classical Hodgkin lymphoma (cHL) and the microenvironment includes aberrant
activity of receptor tyrosine kinases. In this study we evaluated the expression, functionality and prognostic significance of
Insulin-like growth factor-1 receptor (IGF-1R) in cHL. IGF-1R was overexpressed in 55% (44/80) of cHL patients.
Phosphorylated IGF-1R was detectable in a minority of the IGF-1R positive tumor cells. The overall survival (OS, 98%) and 5-
year progression-free survival (PFS, 93%) was significantly higher in IGF-1R positive cHL patients compared to IGF-1R
negative patients (OS 83%, p = .029 and PFS 77%, p = .047, respectively). Three cHL cell lines showed expression of IGF-1R,
with strong staining especially in the mitotic cells and expression of IGF-1. IGF-1 treatment had a prominent effect on the
cell growth of L428 and L1236 cells and resulted in an increased phosphorylation of IGF1R, Akt and ERK. Inhibition of IGF-1R
with cyclolignan picropodophyllin (PPP) decreased cell growth and induced a G2/M cell cycle arrest in all three cell lines.
Moreover, a decrease in pCcd2 and an increase in CyclinB1 levels were observed which is consistent with the G2/M cell cycle
arrest. In conclusion, IGF-1R expression in HRS cells predicts a favorable outcome, despite the oncogenic effect of IGF-1R in
cHL cell lines.
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Introduction
Classical Hodgkin lymphoma (cHL) is characterized by a
minority of malignant Hodgkin and Reed-Sternberg (HRS) cells
that usually represent only about 1% of the total number of cells in
the tumor tissue. The HRS cells are surrounded by a vast majority
of reactive cells including lymphocytes, plasma cells, eosinophils
and histiocytes [1].
HRS cells are dependent on interactions with other cell types
for their survival. These interactions include, among others, tumor
cell activation by multiple receptor tyrosine kinases (RTK), which
have been shown to be overexpressed in HRS cells [2].
The Insulin-like Growth Factor 1 Receptor (IGF-1R) is a
tetrameric receptor tyrosine kinase consisting of two ligand-
binding extracellular a-subunits that are bound by disulfides to
two single transmembrane b-subunits [3]. The molecular structure
of its ligand Insulin-like Growth Factor 1 (IGF-1) is similar to
Insulin. IGF-1 is produced primarily by the liver and bone marrow
stromal cells as an endocrine factor, under the control of
hypothalamic growth hormone releasing hormone and pituitary
growth hormone.
A unique feature of IGF-1R, different from other RTKs, is that
it is in a constitutive dimerized state, even in the absence of its
ligand [4–6]. Upon ligand binding, the three tyrosine residues
(Y1135, Y1131 and Y1136) are transphosphorylated by the
tyrosine kinase (TK) domain of the b-subunit [7], resulting in an
increase in catalytic activity. The phosphorylated tyrosine residues
serve as docking sites for other signaling molecules such as insulin
receptor substrate 1–4 (IRS-1-4) and SRC homology 2 domain-
containing proteins (Shc). These molecules respectively activate
the phosphoinositide 3 kinase (PI3K)/Akt and the mitogen-
activated protein kinase (MAPK) pathways [3,8,9].
Another unique feature of IGF-1R is that at least three PI3K
molecules can be recruited by one IGF-1R. PI3K binds directly to
the pY1316 residue of the C-terminal domain of IGF-1R [10], and
two additional PI3K molecules bind to pY608 and pY939 of IRS-
1 [11]. Activation of Akt exerts anti-apoptotic effects through
inhibitory phosphorylation of pro-apoptotic factors as BAD, as
well as increased expression of anti-apoptotic proteins such as
BCL-2, and BCL-XL [12].
PI3K was found to be constitutively activated in HRS cells and
promoted their survival [13]. The MAPK pathway mediates
diverse biological functions depending upon the cellular context,
including cell growth, survival, and differentiation [14]. Aberrant
IGF-1 signaling has been found in multiple aspects of tumor
biology, including proliferation, transformation, apoptosis protec-
tion and chemotherapy-resistance [15–17]. In hematopoietic
malignancies, a critical role was shown of the IGF-1/IGF-1R
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signaling pathway for proliferation and survival in multiple
myeloma (MM) [18] and mantle cell lymphoma (MCL) [19].
The functionality of IGF-1R in cHL is unknown. In this study we
evaluated the expression, function and prognostic significance of
IGF-1R in cHL.
Materials and Methods
Patient and tissue data
Primary cHL tissues were retrieved from the Department of
Pathology, University Medical Center Groningen, the Netherlands
(n = 80 collected from 1993 to 2010). The basic characteristics of
the patients are presented in Table 1. The histological diagnosis
was based on the currently used criteria defined by the World
Health Organization 2008 classification. The median follow-up
was 55 months (interquartile range, 34.5–104.5 months). The
study protocol was consistent with international ethical guidelines
(the Declaration of Helsinki and the International Conference on
Harmonization Guidelines for Good Clinical Practice). The same
patient cohort was used in an earlier study [20], and according to
the Medical ethics review board of the University Medical Center
Groningen fulfilled requirements for patient anonymity and were
in accordance with their regulations. The Medical ethics review
board waives the need for approval if rest material is used under
law in the Netherlands, and waives the need for informed consent
when patient anonymity is assured.
Immunohistochemistry
Formalin-fixed and paraffin-embedded specimens were cut into
4-mm sections, mounted onto polylysine-coated slides, deparaffi-
nized in xylene, and rehydrated in a graded ethanol series. The
sections were quenched for endogenous peroxidase with 0.3%
hydrogen peroxide, and then boiled in EDTA (1 mmol/L; pH8.0)
for 15 minutes in a microwave oven for antigen retrieval. The
sections were incubated at 37uC for 1 hour with the first antibody,
IGF-1R (1:1000, (3C8B1, 3G5C1 [21,22]), Abcam, Cambridge,
UK) pIGF-1R (Y1161, Abcam) and CD30 (BerH2, Dako,
Glostrup, Denmark), and 30 minutes with horse-radish peroxi-
dase-labeled secondary and tertiary antibodies (Dako). 3,39-
diaminobenzidine (DAB) chromogen (Sigma Aldrich, St Louis,
MO, USA) was used as substrate and sections were counterstained
with hematoxylin. CD30 expression was used to identify the tumor
cells. For positive controls tonsil and breast carcinoma tissue was
used. For negative controls, tissue sections were incubated under
the same experimental conditions without primary antibody. For
immunocytochemistry on the 3 cHL cell lines, cytocentrifuge
preparations were made and fixed with acetone for 10 minutes.
Cells were stained with the primary antibody, and subsequently
incubated with secondary and third antibodies; 3-Amino-9-
ethylcarbazole was used as a chromogen.
Evaluation of IGF-1R expression was performed by a hema-
topathologist without knowledge of the clinical outcome. A case
was defined positive when HRS cells showed homogenous staining
for IGF-1R. Blood vessels in all tissue sections served as internal
controls for IGF-1R. Expression of IGF-1R was correlated to age,
sex, histological subtype, stage of disease, EBV status and with
other known prognostic factors.
Cell lines
The cHL cell lines L428, KM-H2 and L1236 (DSMZ,
Braunschweig, Germany) were cultured in RPMI-1640 medium
supplemented with10% fetal calf serum (5% for L428), ultra-
glutamine, and 100 U/ml penicillin/streptomycin (Lonza, Ver-
viers, Belgium).
IGF-1 levels in cHL cell line culture supernatant
2*105 cells per ml were cultured in triplicate in RPMI 1640 with
FCS and supernatants were collected after 24 hours. IGF-1
protein levels were measured by ELISA (R&D Systems, Minne-
apolis, MN, USA) according to the instructions provided by the
manufacturer. RPMI 1640 supplemented with 10% FCS was used
as the baseline for the levels of secreted IGF-1.
Western blot analysis
Cell lines were starved in medium without serum for 24 hours
and treated with different concentrations of an IGF-1R inhibitor
cyclolignan picropodophyllin (PPP; Calbiochem, Gibbstown, NJ, USA))
Table 1. IGF-1R expression by HRS cells in relation to disease
parameters, EBV status and treatment.
Characteristic






25 (7–83) 35 (8–69) 0.14*
Gender 0.53{
- male 24 (55%) 19 (53%)




- NS 38 (86%) 23 (64%)
- MC 1 (2%) 8 (22%)
- LR 1 (2%) -
- cHL, NOS 4 (9%) 5 (14%)
Ann Arbor Stage 0.93{
- I-II 27 (61%) 21 (58%)
- III-IV 15 (34%) 14 (39%)
- n.a. 2 (5%) 1 (3%)
EBV status 0.36{
- positive 11 (25%) 12 (33%)
- negative 33 (75%) 23 (64%)
- n.a. - 1 (3%)
B-symptoms 0.83{
-present 25 (57%) 19 (53%)
-absent 17 (39%) 16 (44%)
-n.a. 2 (5%) 1 (3%)
IPS 0.67{
-low (0-2) 28 (64%) 22 (61%)
-high ($3) 9 (21%) 10 (28%)
-n.a. 7 (16%) 4 (11%)
Chemotherapy 0.71{
-ABVD 20 (45%) 22 (61%)
-BEACOPP 1 (2%) 1 (3%)
-MOPP/ABVD 7 (16%) 5(14%)
-Pediatric protocols 12 (27%) 6 (17%)
-RT alone 2 (5%) 1 (3%)
-n.a. 2 (5%) 1 (3%)
NS: nodular sclerosis; MC: mixed cellularity; LR: lymphocyte rich; LD: lymphocyte
depleted; NOS: not otherwise specified; n.a. = not available; *Mann-Whitney
test; {Pearson’s chi-squared test.
doi:10.1371/journal.pone.0087474.t001
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for 4 hours. PPP stock solutions were prepared in DMSO (Sigma-
Aldrich) and stored at 4uC in 10 uM aliquots. After 30 minutes of
incubation with exogenous IGF-1 (R&D Systems) at a concentra-
tion of 50 ng/mL, cells were lysed in lysis buffer (Cell Signalling
Technology, Boston, MA, USA) and incubated for 20 minutes on
ice. The cell lysate was centrifuged at 14,000 g for 10 minutes at
4uC to remove cellular debris. The protein concentration was
determined using bicinchonic acid (Pierce Chemical Co., Rock-
ford, IL, USA) according to the manufacturer’s instructions. The
cell lysate was diluted in loading buffer, boiled for 5 minutes and
separated on a 8% or 12% (w/v) Tris-HCl SDS polyacrylamide
gel. Proteins were transferred to a nitrocellulose membrane using
standard protocols and incubated with primary antibodies at 4uC
overnight. Immunostaining was amplified by incubation with
HRP-conjugated antibodies (Dako) and chemiluminescence was
detected using SuperSignalHWest Dura Extended Duration
Substrate (Pierce Chemical Co). Experiments were performed in
triplicate. Antibodies used in the Western blot analyses were anti-
IGF-1R, anti-pIGF-1R (Tyr1135/1136), anti-Akt, anti-pAkt
(D9E, Ser473), anti- 44/42 MAPK (ERK1/2), anti-p44/42
MAPK (ERK1/2, Thr202/Tyr204), anti-Cdc2, anti-pCdc2
(Tyr15), anti-CyclinB1 (V152)(Cell Signaling Technology) and
b–actin (Abcam).
Alamar blue test
Cellular growth after stimulation and inhibition was evaluated
by alamar blue tests (AbDSerotec, Oxford, UK). Alamar blue is a
measurement of metabolic activity, which can be measured at
several time points in the same cells. In the absence of apoptosis,
we used alamar blue as a measurement of relative cell numbers.
Cell lines were seeded at 10,000 cells/ml in 96-well plates and
10 mL of alamar blue was added to each well. The fluorescence
was measured with an excitation of 560 nm and emission at
590 nm. Every cell line was analyzed in triplicate (3 wells) and in
three independent experiments. The fluorescence was measured
with increasing concentrations of IGF-1, PPP or DMSO control at
different time points. Relative percentages of cell growth were
calculated as follows: mean fluorescence treated cells/mean
fluorescence control cells.
Cell cycle assays
For the cell cycle analyses, cells were harvested after 24 hours,
washed in phosphate-buffered saline with 0.1% bovine serum
albumin, and resuspended in 0.5 ml hypotonic PI solution (0.1%
sodium citrate, 0.3% triton X-100, 0.01% propidium iodide and
0.002% ribonucease A). The percentage of cells in specific cell
cycle phases (G1, S, and G2/M) was determined using a flow
cytometer (Calibur, BD Biosciences, San Jose, CA USA) and the
Modfit software. Every sample was tested in three independent
experiments.
Statistical evaluation
The IBM SPSS Statistics 20 software package and GraphPad
Prism were used for the statistical analysis and data plotting. The
Chi-square test or Fisher’s exact test were used to analyze the
associations between clinicopathological features with the IGF1R
expressions, as appropriate. The nonparametric Mann-Whitney
test was used to evaluate the association between patient age and
IGF-1R expression. Proliferation and cell cycle results were
analyzed by a student t-test or one-way analysis of variance
(ANOVA).
Overall survival (OS) was measured from the date of diagnosis
of cHL to the date of death. 5-years Progression-free survival (PFS)
was defined as months elapsed between the date of diagnosis and
the date of tumor progression or death from any cause, with
censoring of patients who were lost to follow-up or still alive and
free of cHL disease at the last date of follow-up. Survival curves
were generated using the method of Kaplan-Meier. The log-rank
test was used to evaluate statistical significance of the differences in
the curves.
Results
IGF-1R expression in cHL tissue
The clinicopathological data of our patient cohort are
summarized in Table 1. Expression of IGF-1R was cytoplasmic
and/or membranous (Figure 1A) in 55% (44/80) of the cHL
patients. Expression of IGF-1R was observed in all or the vast
majority of HRS cells in positive cases, whereas in negative cases
virtually all HRS cells were negative. There was a significant
difference in IGF-1R expression with HL subtype (p = .0157), with
a high percentage of positive cases in the nodular sclerosis cases
(38/61) and a low percentage of positive cases in mixed cellularity
cases (1/9). We found no statistical significant differences in IGF-
1R expression for age, EBV status, Ann Arbor Stage, IPS, B-
symptoms, bulky disease, or treatment. In a pilot study 16 IGF-1R
positive patients were stained for pIGF-1R. Only single HRS cells
stained positive for phosphorylated IGF-1R (Figure 1B) in 3 of the
patients, whereas the HRS cells in the remaining 13 patients were
pIGF-1R negative in all HRS cells. Based on this low percentage
of positive cells we decided not to stain the whole patient cohort.
Prognostic value of IGF-1R
We studied the prognostic value of IGF-1R in our patient
cohort. The overall survival (OS) was significantly higher in the
IGF-1R positive patient group (98%), as compared to the IGF-1R
negative patient group (83%, Figure 2A, p= .029). The 5-year
progression-free survival (PFS) was also significantly better in IGF-
1R positive patients (93%) compared to IGF-1R negative patients
(77%, p= .047, Figure 2B). Thus, absence of IGF-1R expression is
a significant prognostic factor for poor 5-years PFS in our cHL
cohort. This prognostic value of IGF-1R was observed in the
entire cohort, but in subgroup analysis according to stage only
remained prognostic among advanced stage patients due to low
number of cases and events per subgroup. The International
Prognostic Score (IPS) could not predict prognosis among
advanced stage patients in our cohort.
IGF-1R and IGF-1 expression in three cHL cell lines
The 3 cHL cell lines showed IGF-1R staining (Figure 1C, D, E),
with the strongest expression in L428. In all 3 cell lines mitotic cells
expressed higher levels of IGF-1R. Western blot analysis of the
three cHL cell lines revealed different levels of IGF-1Rb subunits
(Figure 3A). L428 cells expressed the highest level of IGF-1R and
KM-H2 the lowest. In order to evaluate a potential autocrine IGF-
1R activation loop, we investigated the production of IGF-1 by the
three cHL cell lines. The IGF-1 level was approximately 100 pg/
ml in the cell culture supernatant after 24 hours of culture and
similar levels were found for all three cell lines (Figure 3B).
L428 cell growth is enhanced by IGF-1
In an attempt to evaluate the potential of IGF-1 stimulation, we
incubated the three cell lines in medium with FCS with different
concentrations of IGF-1. This revealed no impact on cell growth
(data not shown), suggesting that the production of IGF-1 by the
HL cells could be saturating the IGF-1R or that the production of
other factors by the cells masks the putative effect of IGF-1. Next
we performed the same experiment after overnight serum
Prognostic Value of IGF-1R in HL
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starvation. 72 hrs of IGF-1 treatment had the most prominent and
significant effect (31% increase) on the cell growth of L428 cells
(Figure 3C). In L1236 a significant increase in cell growth was
observed only for the high dose of IGF-1 (40 ng/ml, Figure 3D).
No significant effect was observed for KM-H2 (Figure 3E). Thus
L428 cells were most sensitive to IGF-1 treatment, consistent with
its high IGF-1R expression level.
PPP inhibits cell growth of cHL cell lines in a dose and
time dependant way
We next investigated the in vitro anti-proliferative effect of PPP
(0.25–2 mM), without addition of IGF-1, in three cHL cell lines.
PPP significantly suppressed cell growth in a dose dependent
manner with the strongest effects observed at 1 and 2 mM PPP
(Figure S1). The effect of PPP was time dependent and after
72 hours of PPP treatment the viability decreased significantly in
Figure 1. IGF-1R expression in HRS cells. A, Representative cHL case showing expression of IGF-1R in the vast majority of HRS cells. B, pIGF-1R
positive HRS cell. C, IGF-1R expression in L428, showing positive staining in all cells with strong expression in mitotic cells, D, IGF-1R expression in
L1236, showing weak staining in all cells and strong expression in mitotic cells and, E, IGF-1R expression in KM-H2, showing weak staining with more
pronounced expression in mitotic cells.
doi:10.1371/journal.pone.0087474.g001
Figure 2. Kaplan-Meier curves for progression free survival (PFS) and overall survival (OS) in IGF-1R expression defined subgroups
of cHL patients. The overall survival was lower in the IGF-1R negative group (83%) as compared to the IGF-1R positive group (98%; P = 0.029). The 5-
year PFS was lower in the IGF-1R negative group (77%) as compared to the IGF-1R positive group (93%; P = 0.047). Numbers below the graph are the
number of patients for each group included at that time point.
doi:10.1371/journal.pone.0087474.g002
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all three cHL cell lines (Figure 4). The strongest effects were again
observed for L428 cells with a reduction in cell growth of 48%.
The reduction in cell growth was 30% in KM-H2 cells and 26% in
L1236. The higher sensitivity of L428 for PPP is consistent with
the high expression of IGF-1R on L428 cells and the sensitivity to
IGF-1.
PPP induces G2/M-phase arrest in cHL cell lines after
24 hours of PPP treatment
To determine whether inhibition of IGF-1R by PPP has an
effect on the cell cycle, we analyzed distribution of cells over the
different cell cycle fractions by PI staining after 24 hours of
treatment. Treatment with PPP induced G2/M cell cycle arrest in
Figure 3. IGF-1R and IGF-1 expression and the effect of IGF-1 on growth in cHL cell lines. A, Western blot showing expression of IGF-1R in
L428, KM-H2 and L1236. The IGF-1R level was high in L428, moderate in L1236 and low in KM-H2. B, IGF1 protein levels in the culture supernatant of
cHL cell lines. The IGF-1 protein levels were similar in the three cHL cell lines. C, IGF-1 treatment of L428 cells revealed a significant effect on cell
growth. D, L1236 cells showed a significant effect on cell growth upon IGF-1 treatment. E, no effect was seen in KM-H2 cells upon treatment with IGF-
1.
doi:10.1371/journal.pone.0087474.g003
Figure 4. The effect of PPP on growth of cHL cell lines. A, L428 cells. B, L1236 cells. C, KM-H2 cells. Cell growth upon treatment with 2 mM PPP
(black bars) for 1, 2 and 3 days was compared with untreated/DMSO control treatment (white bars). Cell growth was significantly decreased
(P,0.001) in all three cell lines.
doi:10.1371/journal.pone.0087474.g004
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all three cell lines, the number of cells in the G2/M phase
significantly increased from 8% to 45% in L428, from 4% to 48%
in KM-H2 and from 3% to 38% in L1236 (Figure 5, and figure
S2).
The IGF-1R/IGF-1 signaling pathway in cHL cell lines
L428 has the highest expression of IGF-1R, so we used L428 for
studying the IGF-1R/IGF-1 signaling pathway after serum
starvation with IGF-1 stimulation and PPP inhibition. The
optimal time to get a strong signal of IGF-1R phosphorylation
by IGF-1 in L428 was 20–30 minutes (Figure 6A). Stimulation
with IGF-1 revealed an increase of pAkt and pERK1/2
(Figure 6A). After treatment with PPP the IGF-1 induced
phosphorylation of the IGF-1Rb subunit is blocked, while the
total amount of IGF-1Rb was not affected. The induction of pAkt
was effectively blocked by PPP in a dose dependent manner
without altering Akt protein levels. Induction of ERK phosphor-
ylation was induced by PPP (Figure 6B).
We next studied the effect of PPP on cell cycle regulators,
including Cdc-2, pCdc-2 and CyclinB1. PPP inhibited phosphor-
ylation of the cell cycle regulator Cdc-2 and increased CyclinB1,
changes that are consistent with G2/M-phase cell cycle arrest
(Figure 6C).
Discussion
The pathogenesis of cHL remains poorly understood. HRS cells
are derived from germinal center B cells that have lost their B cell
phenotype including immunoglobulin expression [23]. Although
normal germinal center B cells that lack functional immunoglob-
ulin undergo apoptosis, HRS cells escape this programmed cell
death [24,25]. Aberrant activity of multiple RTKs in HRS cells
might prevent apoptosis and explain resistance to treatment-
induced apoptosis and treatment failure. HRS cells aberrantly
express up to 7 different RTKs with extensive heterogeneity
regarding the number and combinations in individual cases [2]. In
general, a more prominent co-expression has been observed in
nodular sclerosis than mixed cellularity cHL [26]. Consistent with
these findings we also found that IGF-1R is predominantly
expressed in the nodular sclerosis subtype of cHL, although we
analyzed a limited number of mixed cellularity HL patients.
Overall we demonstrated IGF-1R expression in the vast majority
of the HRS cells in 55% of the cHL patients. IGF-1R is not
normally expressed by B cells, only some large germinal center B
cells show weak expression, but it is expressed by plasma cells [19].
IGF-1R is expressed by mantle cell lymphomas [19]. So, it is
possible that expression of IGF-1R by the tumor cells in HL can be
an effect of malignant transformation or due to differentiation
towards plasma cells. In cHL expression of IRF4/Mum1,
expressed in germinal center cells and plasma cells, and Blimp-1,
a regulator of plasma cell differentiation, are both detected,
although for Blimp-1 only in 23% of patients in a small part of
tumor cells [27].
We studied expression of IGF-1R and IGF-1 in three cHL cell
lines and observed marked differences in IGF-1R levels, whereas
the levels of IGF-1 production were similar. Cells in the process of
mitosis showed strongly enhanced expression of IGF-1R in all 3
cell lines. The functionality of the IGF-1R/IGF-1 signaling
pathway was studied in L428 cells, which showed the highest
IGF-1R levels. Consistent with its known signaling pathway we
observed enhanced pIGF-1R, pAkt and pERK1/2 levels upon
stimulation with IGF-1. Treatment with the IGF-1R inhibitor PPP
revealed an inhibiting effect on cell growth, and blocked the
constitutive phosphorylation of IGF-1R. It has been shown that
the inhibitory effect of PPP on IGF-IR did not co-inhibit the
insulin receptor activity or compete with ATP in in vitro kinase
assays in several cell lines, suggesting that it may inhibit IGF-1R
autophosphorylation at the substrate level [28]. Although PPP
Figure 6. The effects of IGF-1 and PPP on IGF-1R autophosphorylation and on its downstream signalling proteins and cell cycle
proteins in L428 cells. A, pIGF-1R level was measured at different time points after stimulation with IGF-1 (50 ng/mL). Phosphorylation levels of
IGF-1R, Akt and ERK were increased upon IGF-1 stimulation at 20 and 30 minutes. B, phosphorylation of IGF-1R, and Akt upon IGF-1 stimulation could
be blocked by the pIGF-1R kinase inhibitor PPP in L428 cells. While phosphorylation of ERK was increased by PPP (C) PPP treatment induced a
reduction of Cdc2 phosphorylation and upregulation of CyclinB1, consistent with the occurrence of a G2/M-phase cell cycle arrest.
doi:10.1371/journal.pone.0087474.g006
Figure 5. The effect of PPP on cell cycle progression of cHL cell lines. A, L428 cell cycle analysis. B, L1236 cell cycle analysis. C, KM-H2 cell
cycle analysis. Flow cytometry histograms are given with a fitted analysis model, in which dark gray areas are calculated areas for cells in G0/G1 and
G2 phase and the shaded area is the calculated area for cells in S phase. Cell cycle distribution upon treatment with PPP (2 mM)-treated for 24 hours
revealed a clear G2/M cell cycle arrest in all cell lines. Representative figures are given. Results of triplicate experiments are given in supplementary
figure 2.
doi:10.1371/journal.pone.0087474.g005
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blocked phosphorylation of Akt, it induced phosphorylation of
ERK1/2. These findings are similar to the results previously
reported in melanoma cell lines [29]. PPP possibly induces
ubiquitination of IGF-1R and in turn activates ERK1/2.
In all cell lines PPP caused G2/M cell cycle arrest. Blocking of
the cell cycle is consistent with the decrease in pCdc2 (Tyr15) and
increase in CyclinB1. In MCL cell lines PPP also induced a G2/M
cell cycle arrest, with similar decreased pCdc2 and increased
CyclinB1 levels. In the same study inhibition of IGF-1R with
siRNA was also tested, since small molecule inhibitors can have
nonspecific effects, and this resulted in very similar effects. In the
MCL cell lines apoptosis was induced after 24 hours of treatment
[19], while we did not see an increase of apoptotic cells between 4
to 72 hours of PPP treatment (data not shown). The PPP
dependent effect on the G2/M cell cycle arrest correlates with
the upregulation of IGF-1R expression during mitosis, and
indicates the relevance of IGF-1R signaling for cell division. This
might also fit the low frequency of pIGF-1R positive HRS cells
and is consistent with the low number of HRS cells in mitosis in
cHL tissue. The effect of PPP also highlights a potential
therapeutic application of IGF-1R kinase inhibitors in combina-
tion with conventional G2 phase specific drugs (Vincristin and
Bleomycin) included in the commonly used ABVD regimen in
cHL.
Expression of IGF-1R has been shown to correlate with an
unfavorable prognosis in several types of cancer, e.g. in advanced
oral squamous cell carcinoma [30], but also with a favorable
prognosis in studies in breast cancer [31–33], non small cell lung
cancer [34] and soft tissue sarcoma [35]. In our cohort IGF-1R
positivity was a significant predictor of good outcome in patients
with cHL both for OS and 5-years PFS. How can the adverse
prognosis of IGF-1R negative HRS cells be explained? Previous
studies revealed that low IGF-1R expression is associated with de-
differentiation of various human cancers[36–39], indicating that
IGF-1R expression is lost when cells become more malignant.
Increased MDM2 expression can cause downregulation of IGF-
1R and in some cancers, such as soft tissue sarcoma, MDM2
expression is associated with a more malignant phenotype [40]. In
cHL patients, expression of MDM2 is not associated with
prognosis [41], and we did not find a correlation of MDM2
expression and absence of IGF-1R receptor expression in our
patient cohort (data not shown). Another more likely explanation
for this unexpected positive prognostic effect might be related to
the characteristic histology of cHL with only a very small
percentage of tumor cells in an abundant reactive infiltrate. The
IGF-1/IGF-1R pathway plays important roles in hematopoietic
cell growth and differentiation and normal immune function [42].
There is some evidence of a role for IGF-1R in T cell growth and
function. Activated T cells have an increased number of IGF-1R
molecules, and IGF-1 was shown to enhance anti-CD3 stimulated
proliferation [43]. It can be speculated that activation of IGF-1R
in HRS cells might alter the immunological response of the
reactive cells by shaping the microenvironment in a way that is less
beneficial for survival and growth of the HRS cells.
We recently reported that expression of the oncogenic RTK c-
Met by HRS cells was a marker for good prognosis in HL [20].
Functional studies showed that the effect of c-Met inhibitors was
unfavorable for growth of HL cell lines similar to the effects of
IGF-1R inhibition. There was no correlation of c-Met expression
with IGF-1R expression in this cohort (data not shown). In a
recently published gene expression based model for the prediction
of overall survival, low IGF-1 levels were correlated with a bad
prognosis [44]. These findings are consistent with our results and
support our findings that an active IGF-1/IGF-1R pathway is a
favorable prognostic marker in HL.
In conclusion, we showed expression of IGF-1R in 55% of cHL
patients. In cHL cell lines both IGF-1R and IGF-1 were expressed
and inhibition of IGF-1R induced G2/M arrest. IGF-1R
expression is enhanced in mitotic cells. Despite the oncogenic
effect of IGF-1R in cell lines, IGF-1R expression in HRS cells
predicts a favorable outcome and might be included in future
clinical risk stratification after validation in future large prospective
studies.
Supporting Information
Figure S1 Effect of PPP inhibition on cell growth.
(DOC)
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